Of course, it hasn’t been entirely champagne and canapés. The little unpleasantness of early 2020 – that pandemic, you know – caused a bit of a wobble. A 34% drop in the S&P 500. Ghastly. And then, the tariffs. Oh, the tariffs. A two-day plunge of 10.5%. One felt quite sorry for the traders. Though, naturally, one didn’t express it.
The bottleneck, it appears, resides not in the appetite of consumers, but in the capacity of the foundry. TSMC, that Taiwanese behemoth, finds itself stretched thin, burdened by the demands of an industry intoxicated by the promise of artificial intelligence. The very accelerators that propel this new age are, ironically, limiting its reach. A curious paradox, wouldn’t you agree? It is a reminder that even the most advanced enterprises are, at their core, subject to the limitations of earthly logistics.
Berkshire Hathaway. The name itself sounds like a conspiracy. They didn’t just buy oil, they inhaled it. Chevron, Occidental… names that used to evoke gas stations and road trips now whisper of fortunes and leverage. Twenty-one billion here, twelve billion there… it’s enough to make a sane man question reality. And then the acquisitions. Dominion Energy’s assets? Snapped up like candy. Cove Point? Another piece of the puzzle. It’s a land grab, a frantic scramble for the black gold before the world supposedly turns green. They’re building a fortress, a dividend-spewing monolith fueled by the planet’s dwindling reserves. And the cash? Oh, the cash pile. They weren’t buying growth stocks; they were hoarding ammunition.
The company, once a purveyor of plastic discs, is now presented as a potential analogue to Berkshire Hathaway. This claim warrants scrutiny, not celebration. Mr. Burry’s recent purchase of GameStop shares, while perhaps motivated by a genuine belief in its leadership, feels less like shrewd investment and more like a desperate search for a narrative.
Visa isn’t the biggest sweet in Berkshire’s jar, not by a long shot (a mere 0.9% of the total), but it’s a reliable one. Old Buffett was always going on about ‘moats’ – not the watery kind, mind you, but things that keep the competitors at bay. Visa’s moat is its reach. It’s everywhere!
But does this represent a genuine opportunity for the discerning investor, or merely another gilded cage constructed to ensnare the unwary? The question demands a sober assessment, a peeling back of the layers of hype and illusion.
This AbbVie thing. They’re a “Dividend King.” A king. Seriously? Like they’re royalty because they’ve been handing out a little extra change for fifty years? It’s just… aggressive. But, okay, they’ve been doing it. Fifty years. It’s impressive, I suppose. It means they haven’t completely messed things up for half a century. That’s… a low bar, isn’t it?
To understand Pfizer is to understand the inherent contradictions of the pharmaceutical industry. It is a capital-intensive undertaking, demanding vast sums for research and development. Regulatory hurdles, while necessary, further inflate costs. Competition is relentless, each company striving for dominance in narrowly defined therapeutic niches. The system is rigged, not by malice, but by its very nature. Patents offer a temporary monopoly, allowing for exorbitant profits, but this advantage inevitably erodes as generic alternatives flood the market. This ‘patent cliff,’ as it is euphemistically termed, is not a bug, but a feature.
This acquisition, representing a mere 4.2% addition to the insider’s existing portfolio, is, shall we say, a subtle flourish. It lacks the audacity of conviction, yet possesses the intrigue of a carefully considered wager. The absence of directly held shares in this transaction is, in itself, a statement—a quiet declaration of preference for the shadows of indirect ownership.
Investors remain cautious, and rightly so. Beneath the veneer of record sales lies a considerable debt, a shadow cast by the recent past. Whether this momentum can be sustained is a question best left unanswered, for the future rarely conforms to our expectations. Still, one is compelled to ask: can Carnival navigate these currents and, once again, exceed the market’s indifferent gaze?